Stability Indicating RP-HPLC Method Development and Validation for The Simultaneous Estimation of Flupentixol and Melitracen in API from and Marketed Tablet Dosage form

The present work describes a reverse phase high performance liquid chromatographic method (RP-HPLC) for the simultaneous estimation of Flupentixol and Melitracen in bulk and in tablet dosage form. Chromatographic separation was performed on Hypersil (C18) (250mm x 4.6mm, 5µm) Column, with a mobile phase comprising of a mixture of methanol and Acetonitrile in the ratio of 34:66v/v. The flow rate was 1.0ml/min with detection at 257nm. Retention times of Flupentixol and Melitracen were found to be 1.791min and 3.465min respectively. As per International Conference on Harmonization (ICH) guidelines the method was validated for linearity, accuracy, precision, limit of quantitation, limit of detection, and robustness. Linearity of Flupentixol was found to be in the range of 60-140µg/mL. and that for Melitracen was found to be 30-70µg/mL. The Precision (Repeatability, Intra-day and Inter-day) of the Flupentixol and Melitracen was found to be within the limits. The correlation coefficients were 0.999 and 0.999 for Flupentixol and Melitracen respectively. The mean recoveries obtained for Flupentixol and Melitracen were 100.28% and 99.79%. This demonstrates that the developed method is simple, precise, accurate, reproducible and rapid for simultaneous estimation of these drugs in bulk and in tablet dosage forms.